AADI BIOSCIENCE, INC.

(AADI)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
12.16 USD   -8.23%
06/24AADI BIOSCIENCE : Corporate Overview
PU
06/24Aadi Bioscience to Join Russell 2000 and Russell 3000 Indexes
AQ
06/23Aadi Bioscience to Join Russell 2000, Russell 3000 Indexes
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $2.3M

05/12/2022 | 08:57am EDT


© MT Newswires 2022
All news about AADI BIOSCIENCE, INC.
06/24AADI BIOSCIENCE : Corporate Overview
PU
06/24Aadi Bioscience to Join Russell 2000 and Russell 3000 Indexes
AQ
06/23Aadi Bioscience to Join Russell 2000, Russell 3000 Indexes
MT
06/23Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
AQ
06/17AADI BIOSCIENCE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/01Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
AQ
05/31Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corp..
AQ
05/31Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corp..
CI
05/26Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial ..
AQ
05/26Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT ..
CI
More news
Analyst Recommendations on AADI BIOSCIENCE, INC.
More recommendations
Financials (USD)
Sales 2022 14,4 M - -
Net income 2022 -60,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,26x
Yield 2022 -
Capitalization 255 M 255 M -
Capi. / Sales 2022 17,7x
Capi. / Sales 2023 16,2x
Nbr of Employees 54
Free-Float 86,4%
Chart AADI BIOSCIENCE, INC.
Duration : Period :
Aadi Bioscience, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 12,16 $
Average target price 43,50 $
Spread / Average Target 258%
EPS Revisions
Managers and Directors
Neil P. Desai President, CEO, Secretary & Director
Scott M. Giacobello Treasurer, Chief Financial & Accounting Officer
Caley M. Castelein Chairman
Loretta M. Itri Chief Medical Officer
Berta Grigorian Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
AADI BIOSCIENCE, INC.-49.65%255
CSL LIMITED-7.99%90 814
SAMSUNG BIOLOGICS CO.,LTD.-7.97%45 825
WUXI BIOLOGICS (CAYMAN) INC.-24.42%41 498
BIOGEN INC.-11.67%31 038
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.19%24 084